Bristol Myers Squibb builds drug R&D supercomputer with Nvidia

Bristol Myers Squibb is significantly expanding its computational infrastructure for drug discovery, deploying an Nvidia DGX SuperPOD supercomputer that the company describes as the most powerful single-owned AI system in the life sciences sector.

The pharmaceutical company announced the expansion on July 20, building on a three-year collaboration with Nvidia that began with its initial deployment of DGX SuperPOD infrastructure. The new system will incorporate AIDGX Vera Rubin NVL72 configurations, which Bristol Myers Squibb claims will deliver both exceptional computing power and energy efficiency for its research operations.

Why it matters

Major pharmaceutical companies are racing to build proprietary AI infrastructure rather than relying solely on cloud providers or external partnerships. Bristol Myers Squibb's investment signals a strategic bet that owning and controlling advanced computing resources will provide a competitive advantage in identifying promising drug candidates earlier and with greater precision. The move toward what the company calls "hybrid intelligence"—AI systems working in tandem with human scientists—represents a practical model for how computational tools may reshape research workflows across the industry.

Advancing the hybrid intelligence model

Bristol Myers Squibb frames the infrastructure expansion as enabling what it calls "hybrid intelligence," where AI systems function as co-scientists alongside human researchers. According to Chief Research Officer Robert Plenge, the objective is to free scientists from manual tasks so they can focus on questions requiring human judgment. "The goal isn't speed for its own sake; it's raising the probability that each program we advance is the right one," Plenge stated.

Chief Digital and Technology Officer Greg Meyers indicated the company is already seeing returns from its AI investments in both pipeline development and operational efficiency. A company spokesperson told Fierce Biotech that Bristol Myers Squibb views its various AI initiatives—including separate collaborations with Anthropic's Claude for R&D and Microsoft for lung cancer diagnostics—as complementary elements of a broader strategy.

Industry-wide infrastructure race

Bristol Myers Squibb's move reflects broader momentum among pharmaceutical companies investing heavily in AI computing capacity. Eli Lilly established an AI co-innovation lab with Nvidia backed by a collective $1 billion commitment over five years. Roche has announced a "hybrid-cloud AI factory" for therapeutic and diagnostic development, while Qiagen partnered with Nvidia to enhance drug discovery capabilities.

The competition for advanced AI infrastructure underscores how computational power has become a strategic asset in pharmaceutical research, with companies betting that superior systems will translate into faster identification of viable drug candidates and more efficient development processes.

Details of the expanded partnership were first reported by Fierce Biotech.